qXR-CTR
Regulatory Status Disclosed
Overview
qXR-CTR by Qure.ai Technologies is a deep learning-based computer vision algorithm designed to automate the assessment of the cardiothoracic ratio (CTR) on chest radiographs. The tool is engineered to assist in identifying radiographic markers associated with cardiomegaly and heart failure risk.
What it does and notable capabilities:
- Automatically measures the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity on posterior-anterior (PA) view chest X-rays.
- Provides automated CTR calculations to support objective assessment of cardiac enlargement.
- Delivers rapid processing to assist clinicians in identifying potential indicators of heart failure.
Who it is for and workflow integration:
- Target Users: Radiologists, cardiologists, emergency physicians, and general practitioners.
- Care Settings: Inpatient and outpatient environments, including hospitals, clinics, and residential care facilities.
- Workflow Integration: The algorithm functions as a pre-read assistant within existing imaging workflows, integrating with PACS to provide automated measurements and passive notifications for worklist prioritization. It is designed to be used alongside standard clinical interpretation and is not intended as a standalone diagnostic tool.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Use Cases
- Automated assessment of cardiothoracic ratio (CTR) on chest X-rays
- Identifying heart failure risk
- Aid in diagnosing and monitoring heart conditions
- Workflow triage for physicians in inpatient and outpatient settings
- Reducing radiologist workload
- Early detection of cardiac and respiratory conditions
What Physicians Need to Know
Heart Failure Risk Prediction
qXR-CTR is an AI-powered solution that assesses the cardiothoracic ratio (CTR) on chest X-rays, which is a key indicator for cardiomegaly and a potential marker for heart failure risk. It can also jointly screen for increased CTR and pleural effusion, both associated with heart failure. Studies have shown its promising potential in incidentally detecting heart failure risk, with one study reporting 77% of flagged patients indicating heart failure upon confirmatory tests. The qXR algorithm has demonstrated a mean sensitivity of 90% and specificity of 80% in detecting heart failure risk. Overall, qXR has an accuracy of 84% in heart failure diagnosis.
Real-Time Alert Capability
The qXR platform, which includes qXR-CTR, provides rapid analysis of chest X-rays, typically processing images in less than 60 seconds, and in some cases, under 20 seconds. This speed allows for efficient diagnoses and can aid in early detection. The system can integrate into existing workflows and serve as a passive notification system for worklist prioritization.
Physician Tip
qXR-CTR is a valuable AI tool for automating cardiothoracic ratio (CTR) assessment on chest X-rays, aiding in the early identification of cardiomegaly and potential heart failure risk. It can help prioritize cases by quickly flagging abnormalities, thereby reducing reporting turnaround times and allowing radiologists to focus on more complex cases. However, it's crucial to remember that qXR-CTR's results are intended to aid physicians and should not be used as a standalone basis for clinical decision-making. Clinical assessment and confirmatory tests remain essential for definitive diagnosis and patient management.
qXR-CTR is designed to integrate into existing standard of care workflows. It can be deployed on cloud or on-premise systems. The Qure.ai app, which supports multi-modality imaging, can be configured with Picture Archiving and Communication Systems (PACS) and modalities to streamline image viewing and utilize Qure's AI-powered solutions.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. |
| Mobile App | 1 |
| API Available | Unknown |
| Data Export | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| GDPR | Yes AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Radiology |
What the Web Says
qXR-CTR by Qure.ai is an AI-powered solution designed to automate the measurement of the cardiothoracic ratio (CTR) on chest X-rays, aiding in the detection of cardiomegaly and potential heart failure. It has received FDA clearance and is intended for use by physicians in various healthcare settings. The software aims to enhance diagnostic accuracy and efficiency, particularly in high-volume environments.
Overall: PositiveStrengths
- Automates CTR assessment, saving time for physicians.
- Enhances diagnostic accuracy for cardiomegaly and heart failure risk.
- Can screen for increased CTR and pleural effusion, both indicators of heart failure.
- Integrates with existing radiology workflows and IT systems.
- High negative predictive value (99%) in segregating normal chest X-rays, helping to clear reporting backlogs.
- Fast processing, with reports generated in under 20 seconds.
Limitations
- Potential for false positives.
- Some users report that AI can slow down workflow by requiring filtering of irrelevant details.
- Requires a fast and smooth internet connection for optimal performance.
- Cost may be considered high by some users.
- Some results may still require manual review.
- One Reddit user reported issues with overcalling opacities and pneumothorax, leading to unnecessary procedures and clinical teams requesting its removal.
Based on reviews from: itnonline.com, recenthealthtech.com, fda.gov, bmj.com, doh.gov.ae, auntminnie.com, oup.com, nih.gov, dicardiology.com, qure.ai, diagnosticsworldnews.com, reddit.com, g2.com, diagnosticimaging.com, yespress.io, itu.int
Last updated: 2026-10-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate qXR-CTR
Press & Coverage
qure.ai
FDA Clears Qure.ai's qXR-CTR Chest X-ray Solution as a Potential Indicator for Identifying Heart Failure Risk
Qure.ai announced FDA clearance for its qXR-CTR solution, an AI-enabled chest X-ray tool that measures the cardiothoracic ratio (CTR) to help identify heart failure risk. This marks Qure.ai's 12th FDA-cleared algorithm and a significant advancement in AI-driven medical imaging for cardiac care.
2023-09
Applied Radiology
AI-Enabled Chest X-ray for Cardiothoracic Ratio from Qure.ai Receives FDA Clearance
Qure.ai's qXR-CTR, an AI-powered chest X-ray solution for measuring the cardiothoracic ratio (CTR), has received FDA clearance. This deep-learning algorithm automates CTR assessment on chest radiographs, aiming to improve diagnostic accuracy and efficiency in identifying heart failure risk.
2023-10
qure.ai
FDA Clears Qure.ai's qXR-CTR Chest X-ray Solution as a Potential Indicator for Identifying Heart Failure Risk
Qure.ai's qXR-CTR, a deep-learning based software, received FDA clearance for automated assessment of the cardiothoracic ratio (CTR) on chest X-rays (CXRs) for adults aged 22 and above. The device is intended to aid physicians in healthcare settings, but its results are not for stand-alone clinical decision-making.
2023-09
qure.ai
Revolutionizing Healthcare: Qure.AI's Innovations in Medical Diagnosis and Treatment
This article highlights Qure.ai's AI-driven chest X-ray interpretation tool, qXR, and its impact on healthcare diagnostics, including the detection of lung nodules, heart failure, and tuberculosis. Clinical studies have shown qXR's effectiveness with high sensitivity and specificity in various detections and an 84% accuracy in heart failure diagnosis.
2024-06
qure.ai
The diagnostic value of chest X-ray scanning by the help of Artificial Intelligence in Heart Failure (ART-IN-HF)
A study on Qure.ai's platform analyzed anonymized chest X-rays from 10,100 patients to detect heart failure, finding 183 patients with increased cardiothoracic ratio (CTR) and pleural effusion. Among those who underwent further tests, 77% were diagnosed with heart failure, demonstrating an 84% accuracy in diagnosis using AI-analyzed images.
2023-08
nih.gov
Radiograph accelerated detection and identification of cancer in the lung (RADICAL): a mixed methods study to assess the clinical effectiveness and acceptability of Qure.ai artificial intelligence software to prioritise chest X-ray (CXR) interpretation.
This study protocol outlines a mixed-methods study to evaluate the clinical effectiveness and acceptability of Qure.ai's 'qXR' software in prioritizing suspicious chest X-rays for lung cancer. The primary objective is to assess qXR's effectiveness in prioritizing patients for follow-up CT scans.
2024-09
qure.ai
Qure.ai nets six new indications cleared by the FDA, taking the chest X-ray crown in the radiology AI race
Qure.ai received FDA 510(k) Class II clearance for qXR-Detect, its latest computer-assisted detection radiography solution, adding six new indications to its chest X-ray AI algorithms. This clearance brings Qure.ai's total FDA-cleared indications to 26 across 9 products, making it a leader in chest X-ray regulatory clearances globally.
2026-02
qure.ai
FDA Clears Qure.ai's qXR-LN, qER (V2.0), qER-Quant, qCT-Quant, qXR-BT, qXR-PTX-PE, and qXR-CTR
Qure.ai lists its US FDA 510(k) cleared products, including qXR-CTR, which is computer-aided detection and localization software. The company also notes its Class IIa CE certification for qXRv3.1 and qERv2.0 EU products under the EU MDD, and Class IIb CE certification for qXRv4.0, qER-NCCT, qCT, and qMSK under the EU MDR.
unknown
Frequently Asked Questions
qXR-CTR is an AI-powered chest X-ray solution that automates the assessment of the cardiothoracic ratio (CTR). It precisely measures the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity, which is a key indicator for cardiomegaly and can help identify potential heart failure risk.
Yes, qXR-CTR has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Qure.ai also states that it complies with HIPAA by de-identifying data for cloud processing or allowing on-premise processing within the covered entity's servers.
While qXR-CTR provides automated CTR assessment, its results are not intended to be used as a stand-alone basis for clinical decision-making. It should not preclude a comprehensive clinical assessment of cardiothoracic ratio cases. Additionally, while CTR is widely used, some research indicates that a universal CTR cut-off value of 50% may be a poor indicator of cardiac enlargement, and a normal CTR does not reliably exclude cardiac pathology.
While qXR-CTR specifically focuses on automated CTR assessment, other AI solutions in radiology offer broader capabilities. Companies like Aidoc, Lunit, and Annalise.ai provide AI software for radiologists with varying focuses such as emergency CT triage, cancer detection, and comprehensive findings. Other companies like Philips Healthcare, Siemens Healthineers, and GE Healthcare offer imaging systems with integrated AI for diagnostics.
Qure.ai generally uses an enterprise pricing model, and specific pricing for qXR-CTR is not publicly listed. Interested parties are advised to contact Qure.ai sales directly for pricing information.
Compare qXR-CTR
VS
qXR-CTR vs Cardiomo
qXR-CTR and Cardiomo are adjacent tools in cardiology AI, addressing different aspects of heart health. qXR-CTR focuses on automated cardiothoracic ratio assessment from chest X-rays for heart size…
VS
qXR-CTR vs PMcardio
Both qXR-CTR and PMcardio are AI tools focused on cardiology, but they analyze different diagnostic inputs. qXR-CTR specializes in automating cardiothoracic ratio measurements from chest X-rays to assess…
VS
qXR-CTR vs EchoNext
Both qXR-CTR and EchoNext are AI tools focused on cardiac health assessment and are FDA-cleared and HIPAA compliant. However, qXR-CTR specializes in analyzing chest X-rays to measure cardiothoracic…
VS
qXR-CTR vs iPredict Eye Screening
While both tools leverage AI for disease screening and include cardiovascular risk assessment, qXR-CTR specifically focuses on automated cardiothoracic ratio measurement from chest X-rays for heart size and…
Suggest an Edit → | Report an issue
| Last Verified: 2026-04-19 | First Added: 2026-04-19